Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
bioRxiv ; 2024 Jun 23.
Artículo en Inglés | MEDLINE | ID: mdl-38948874

RESUMEN

Gene therapies have the potential to treat disease by delivering therapeutic genetic cargo to disease-associated cells. One limitation to their widespread use is the lack of short regulatory sequences, or promoters, that differentially induce the expression of delivered genetic cargo in target cells, minimizing side effects in other cell types. Such cell-type-specific promoters are difficult to discover using existing methods, requiring either manual curation or access to large datasets of promoter-driven expression from both targeted and untargeted cells. Model-based optimization (MBO) has emerged as an effective method to design biological sequences in an automated manner, and has recently been used in promoter design methods. However, these methods have only been tested using large training datasets that are expensive to collect, and focus on designing promoters for markedly different cell types, overlooking the complexities associated with designing promoters for closely related cell types that share similar regulatory features. Therefore, we introduce a comprehensive framework for utilizing MBO to design promoters in a data-efficient manner, with an emphasis on discovering promoters for similar cell types. We use conservative objective models (COMs) for MBO and highlight practical considerations such as best practices for improving sequence diversity, getting estimates of model uncertainty, and choosing the optimal set of sequences for experimental validation. Using three relatively similar blood cancer cell lines (Jurkat, K562, and THP1), we show that our approach discovers many novel cell-type-specific promoters after experimentally validating the designed sequences. For K562 cells, in particular, we discover a promoter that has 75.85% higher cell-type-specificity than the best promoter from the initial dataset used to train our models.

2.
bioRxiv ; 2023 Feb 27.
Artículo en Inglés | MEDLINE | ID: mdl-36909524

RESUMEN

Advances in gene delivery technologies are enabling rapid progress in molecular medicine, but require precise expression of genetic cargo in desired cell types, which is predominantly achieved via a regulatory DNA sequence called a promoter; however, only a handful of cell type-specific promoters are known. Efficiently designing compact promoter sequences with a high density of regulatory information by leveraging machine learning models would therefore be broadly impactful for fundamental research and direct therapeutic applications. However, models of expression from such compact promoter sequences are lacking, despite the recent success of deep learning in modelling expression from endogenous regulatory sequences. Despite the lack of large datasets measuring promoter-driven expression in many cell types, data from a few well-studied cell types or from endogenous gene expression may provide relevant information for transfer learning, which has not yet been explored in this setting. Here, we evaluate a variety of pretraining tasks and transfer strategies for modelling cell type-specific expression from compact promoters and demonstrate the effectiveness of pretraining on existing promoter-driven expression datasets from other cell types. Our approach is broadly applicable for modelling promoter-driven expression in any data-limited cell type of interest, and will enable the use of model-based optimization techniques for promoter design for gene delivery applications. Our code and data are available at https://github.com/anikethjr/promoter_models.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...